IONS - Ionis Pharmaceuticals, Inc.

Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match

Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.

Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q1 Earnings

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 13% and 0.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

• 
  MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

  Zacks
• 
  Tsakos Energy (TNP) Surpasses Q1 Earnings and Revenue Estimates

  Zacks

Avalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Could This Rare-Disease Drug Candidate Become a Blockbuster?

This drug candidate could be a great treatment option for patients with a potentially deadly disease.

Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study

Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Why Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down

Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to Decline

Relay Therapeutics, Inc. (RLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Institutional investors in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) lost 4.6% last week but have reaped the benefits of longer-term growth

Every investor in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) should be aware of the most powerful shareholder groups...

Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?

Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have endured a 41% loss from investing in the stock three years ago

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Why Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe

Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.

Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines

Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.

Should You Be Worried About Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 1.2% Return On Equity?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up

Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Ionis (IONS) This Earnings Season?

Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.